灵康药业：2025年第一次临时股东大会决议公告

Group 1 - The core point of the article is that Lingkang Pharmaceutical announced the convening of its first extraordinary general meeting of shareholders in 2025, which took place on July 30, 2025, to review and approve the proposal to adjust the conversion price of "Lingkang Convertible Bonds" [2] Group 2 - The company is taking steps to modify the terms of its convertible bonds, which may impact its capital structure and investor sentiment [2] - The announcement reflects the company's ongoing efforts to manage its financial instruments effectively [2] - The decision to adjust the conversion price indicates a strategic move to enhance shareholder value and potentially attract more investment [2]